Improving the Solubility and Bioavailability of Dihydroartemisinin by Solid Dispersions and Inclusion Complexes

다국어 초록 (Multilingual Abstract)

Dihydroartemisinin (DHA) is a poorly water-soluble drug that displays low bioavailability after oral administration. Attempts have been made to improve the solubility of DHA. Yet, no information is available concerning improved bioavailability. This study aimed to improve the water solubility of DHA by two systems: solid dispersions with polyvinylpyrrolidone (PVPK30, PVPK25, PVPK15) and inclusion complexes with hydroxypropyl-β-cyclodextrin (HPβCD), as well as improving the bioavailability of both systems. The phase transition of DHA with hydrophilic polymers was evaluated by X-ray diffraction (XRD) and differential scanning calorimetery (DSC). DHA became amorphous in DHA-HPβCD complexes and showed more amorphous behavior in XRD analyses with rise in molecular weight of PVP. Melting onset temperature of DHA decreased, while DSC thermograms revealed the peak area and enhanced enthalpy change (DH) in solid dispersions as well as inclusion complexes. DHA solubility was enhanced 84-fold in DHA-HPβCD complexes and 50-times in DHA-PVPK30. The improved solubility using the four polymers was in the following order: HPβCD > PVPK30 > PVPK25 > PVPK15. Values of area under curve (AUC) and half life (t_(1/2)) of DHA-PVPK30 were highest followed by DHA- HPβCD, DHA-PVPK15 and DHA-PVPK25. Vd/f of DHA-PVPK30 was 7-fold. DHA- HPβCD, DHA-PVPK15 and DHA-PVPK25 showed significantly different pharmacokinetic parameters compared with DHA solutions. The 95% confidence interval was meaningful in AUC and t_(1/2).
Pharmacokinetic parameters revealed that all four-test preparations were significantly more bioavailable than DHA alone.

참고문헌 (Reference)

1 Li, Q. G., "The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats" 50 : 173-182, 1998

2 Ahuja, N., "Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers" 65 : 26-38, 2007

3 Nontprasert, A., "Studies of the neurotoxicity of oral artemisinin derivatives in mice" 62 : 409-412, 2000

4 Ambike, A., "Stability study of amorphous valdecoxib" 282 : 151-162, 2004

5 Dordunoo, S. K, "Solubility and stability of taxol: effects of buffers and cyclodextrins" 133 : 191-201, 1996

6 Martinez-Ohárriz, M. C., "Solid dispersions of diflunisal-PVP: polymorphic and amorphous states of the drug" 28 : 717-725, 2002

7 Sethia, S., "Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods" 272 : 1-10, 2004

8 Muhammad Tayyab Ansari, "Solid Dispersions of ihydroartemisinin in Polyvinylpyrrolidone" 대한약학회 31 (31): 390-398, 2008

9 Cirri, M., "Simultaneous effect of cyclodextrin complexation, pH, and hydrophilic polymers on naproxen solubilization" 42 : 126-131, 2006

10 Batty, K. T., "Selective high-performance liquid chromatographic determination artesunate and α- and β- dihydroartemisinin in patients with falciparum malaria" 677 : 345-350, 1996

11 Batty, K. T., "Protein binding and α:β anomer ratio of dihydroartemisinin in vivo" 57 : 529-533, 2004

12 Kabanov, A. V., "Pluronic block copolymers: novel functional molecules for gene therapy" 54 : 223-233, 2002

13 Bikiaris, D., "Physicochemical studies on solid dispersions of poorly water-soluble drugs: evaluation of capabilities and limitations of thermal analysis techniques" 439 : 58-67, 2005

14 Andrews, G. P., "Physicochemical characterization of hot melt extruded bicalutamidepolyvinylpyrrolidone solid dispersions" 99 : 1322-1335, 2010

15 Trapani, G., "Physicochemical characterization and in vivo properties of Zolpidem in solid dispersions with polyethylene glycol 4000 and 6000" 184 : 121-130, 1999

16 Fernandes, C. M., "Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds" 15 : 79-88, 2002

17 Muhammad Tayyab Ansari, "Physicochemical Characterization of Artemether Solid Dispersions with Hydrophilic Carriers by Freeze Dried and Melt Methods" 대한약학회 33 (33): 901-910, 2010

18 Higuchi, T., "Phase solubility techniques" 4 : 117-212, 1965

19 Navaratnam, V., "Pharmacokinetics of artemisinin-type compounds" 39 : 255-270, 2000

20 Binh, T. Q., "Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria" 51 : 541-546, 2001

21 "Monographs for Antimalarial Drugs, In International Pharmacopoeia" WHO Press 215-218, 2004

22 Palmieri, G. F., "Lonidamine solid dispersions: in vitro and in vivo evaluation" 28 (28): 1241-1250, 2002

23 Illapakurthy, A. C., "Interaction of artemisinin and its related compounds with hydroxypropyl-β-cyclodextrin in solution state: experimental and molecular-modeling studies" 92 : 649-655, 2003

24 Liu, X., "Inclusion of acitretin into cyclodextrins: phase solubility, photostability, and physicochemical characterization" 92 : 2449-2457, 2003

25 Emara, L. H., "Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers" 28 : 795-807, 2002

26 Van Nijlen, T., "Improvement of the dissolution rate of artemisinin by means of supercritical fluid technology and solid dispersions" 254 : 173-181, 2003

27 Wong, J. W, "Improved oral bioavailability of artemisinin through inclusion complexation with β- and γ-cyclodextrins" 227 : 177-185, 2001

28 Keoluangkhot, V., "Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether" 78 : 552-555, 2008

29 Wagner, J. G., "Fundamentals of clinical pharmacokinetics" Drug Intelligence Publications 1975

30 Wu, K., "Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent" 98 : 2422-2431, 2009

31 Narang, A. S., "Evaluation of solid dispersions of clofazimine" 28 : 1001-1013, 2002

32 Shinde, V. R., "Enhanced solubility and dissolution rate of lamotrigine by inclusion complexation and solid dispersion technique" 60 : 1121-1129, 2008

33 Min-Young Heo, "Effect of Solubilizing and Microemulsifying Excipients in Polyethylene Glycol 6000 Solid Dispersion on Enhanced Dissolution and Bioavailability of Ketoconazole" 대한약학회 28 (28): 604-611, 2005

34 Muhammad Tayyab Ansari, "Dihydroartemisinin-cyclodextrin Complexation: Solubility and Stability" 대한약학회 32 (32): 155-165, 2009

35 de Araujo, D. R., "Development of pharmacological evaluation of ropivacaine-2-hydroxypropyl-β- cyclodextrin inclusion complex" 33 : 60-71, 2008

36 Kang, J., "Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent" 15 : 163-170, 2002

37 Tommasini, S., "Combined effect of pH and polysorbates with cyclodextrins on solubilization of naringenin" 36 : 327-333, 2004

38 de Vries, P. J., "Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria" 52 : 818-836, 1996

39 Marin, M. T., "Characterization and solubility study of solid dispersions of flunarizine and polyvinylpyrrolidone" 57 : 723-727, 2002

40 Esclusa-Diaz, M. T., "Characterization and in vitro dissolution behaviour of ketoconazole/ β- and 2-hydroxypropyl-β-cyclodextrin inclusion compounds" 143 : 203-210, 1996

41 Nagarsenker, M. S., "Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage" 31 : 169-178, 2005

42 Fawaz, F., "Bioavailability of norfloxacin from PEG 6000 solid dispersion and cyclodextrin inclusion complexes in rabbits" 132 : 271-275, 1996

43 Ashton, M., "Artemisinin pharmacokinetics in healthy adults 250, 500 and 1000 mg single oral doses" 19 : 245-250, 1998

44 Silamut, K., "Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria" 47 : 3795-3798, 2003